Sanofi Pasteur announces availability of Sklice head lice lotion

Head lice affects 6 million to 12 million children per year

SWIFTWATER, Pa. — Sanofi's vaccine's division has launched a new treatment for head lice, the company said Monday.

Sanofi Pasteur announced the availability of Sklice (ivermectin) lotion in the 0.5% strength. The drug is approved for patients ages 6 months and older.

The company said head lice cases have increased rapidly in the United States, affecting between 6 million and 12 million children ages 3 to 11 years each year.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.